Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Many DNA tumor viruses promote cellular transformation by inactivating the critically important tumor suppressor protein p53. In contrast, it is not known whether p53 function is disrupted by hepatitis C virus (HCV), a unique, oncogenic RNA virus that is the leading infectious cause of liver cancer in many regions of the world. Here we show that HCV-permissive, liver-derived HepG2 cells engineered to constitutively express microRNA-122 (HepG2/miR-122 cells) have normal p53-mediated responses to DNA damage and that HCV replication in these cells potently suppresses p53 responses to etoposide, an inducer of DNA damage, or nutlin-3, an inhibitor of p53 degradation pathways. Upregulation of p53-dependent targets is consequently repressed within HCV-infected cells, with potential consequences for cell survival. Despite this, p53 function is not disrupted by overexpression of the complete HCV polyprotein, suggesting that altered p53 function may result from the host response to viral RNA replication intermediates. Clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9-mediated ablation of double-stranded RNA (dsRNA)-activated protein kinase R (PKR) restored p53 responses while boosting HCV replication, showing that p53 inhibition results directly from viral activation of PKR. The hepatocellular abundance of phosphorylated PKR is elevated in HCV-infected chimpanzees, suggesting that PKR activation and consequent p53 inhibition accompany HCV infection in vivo . These findings reveal a feature of the host response to HCV infection that may contribute to hepatocellular carcinogenesis. IMPORTANCE Chronic infection with hepatitis C virus (HCV) is the leading cause of liver cancer in most developed nations. However, the mechanisms whereby HCV infection promotes carcinogenesis remain unclear. Here, we demonstrate that HCV infection inhibits the activation of p53 following DNA damage. Contrary to previous reports, HCV protein expression is insufficient to inhibit p53. Rather, p53 inhibition is mediated by cellular protein kinase R (PKR), which is activated by HCV RNA replication and subsequently suppresses global protein synthesis. These results redefine our understanding of how HCV infection influences p53 function. We speculate that persistent disruption of p53-mediated DNA damage responses may contribute to hepatocellular carcinogenesis in chronically infected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG 2 HCV replication inhibits p53 activation following DNA damage. (A) Immunofluorescence confocal microscopy for p53 and HCV core protein in HepG2/miR-122 cells electroporated with genome-length HCV RNA (JFH1-QL) or a nonreplicating control RNA (JFH1/GND) and treated 72 h later with 100 μM etoposide (ETOP) or DMSO for 2 h. Nuclei were labeled with DAPI. Bars, 50 μm. (B) Immunoblots of p53, p21, PUMA, and HCV core protein in HepG2/miR-122 cells electroporated with JFH1-QL or JFH1/GND RNA and treated 72 h later with 50 μM ETOP, 10 μM MDM2 inhibitor (nutlin-3), or DMSO for 6 h. β-Tubulin was used as a loading control. (C) Flow cytometric analysis of p53 and HCV core protein levels in cells treated as described for panel A. Quadrants are based on staining with isotype control antibodies. The frequency of events in each quadrant is represented as the percentage of total gated events. (D) p53 accumulation in cell populations from panel C that do not express HCV core [HCV core (-)] versus cell populations that express HCV core [HCV core (+)]. The numbers indicate the percentages of p53-positive cells following etoposide treatment. (E) Median fluorescence intensity (MFI) values for p53 for the indicated populations are shown normalized to JFH1/GND-electroporated, DMSO-treated controls. Relative MFI values represent the means plus standard errors of the means (SEM) (error bars) from three independent experiments. (F) p21 upregulation in HCV core (-) versus HCV core (+) cells treated with 50 μM ETOP or DMSO for 6 h. The numbers indicate the percentages of p21-positive cells following etoposide treatment. (G) MFI values for p21 are shown normalized to JFH1/GND-electroporated, DMSO-treated controls. Relative MFI values represent the means plus SEM from three independent experiments. Values that are significantly different (P < 0.0001), by two-way analysis of variance (ANOVA) with Bonferroni’s correction for multiple comparisons are indicated by a bar and three asterisks.](https://figures.cochat.ai/paper-figures/077c24eda53649a09e8f3e666b4c76d3/hepatitis-c-virus-indirectly-disrupts-dna-damage-induced-p53-responses-by-figure-2.jpg)
![FIG 3 p53 activation is impaired in cells inoculated with infectious HCV. (A) Flow cytometric analysis of HepG2-HFL cells 72 h after mock infection or inoculation with JFH1-QL virus (MOI of 0.5). Cells were gated into mock-infected (-) versus virus-infected (+) populations based on HCV core protein staining in mock-infected cells. The percentage of cells in each population is indicated. (B) p53 accumulation in cells that do not express HCV core [HCV core (-)] versus cells that express HCV core [HCV core (+)]. The cells were treated with 50 μM etoposide or DMSO control for 6 h. Numbers indicate the percentages of p53-positive cells following etoposide treatment. (C) p21 upregulation in HCV core (-) cells versus HCV core (+) cells treated as described for panel B. Numbers indicate the percentages of p21-positive cells following etoposide treatment.](https://figures.cochat.ai/paper-figures/604ee7624f09433791460b76de22b5fe/hepatitis-c-virus-indirectly-disrupts-dna-damage-induced-p53-responses-by-figure-3.jpg)

![FIG 5 p21 and p53 transcript levels during HCV infection. (A) RNA flow cytometric analysis of HCV RNA-electroporated HepG2/miR-122 cells. Cells were gated into uninfected (-) versus infected (+) populations based on detection of HCV RNA. (B) p21 mRNA levels in cells without HCV RNA [HCV RNA (-)] versus cells with HCV RNA [HCV RNA (+)]. The cells were treated with 50 μM ETOP or DMSO control for 6 h. (C) p53 mRNA levels in HCV RNA (-) cells versus HCV RNA (+) cells treated as described for panel B.](https://figures.cochat.ai/paper-figures/b5540dde4e1b4efa9b875fcf6ba74454/hepatitis-c-virus-indirectly-disrupts-dna-damage-induced-p53-responses-by-figure-5.jpg)
![FIG 6 HCV inhibition of p53 activation is independent of MDM2 and proteasome activity. (A) p53 accumulation in HCV core (-) versus HCV core (+) populations of HepG2/miR-122 cells electroporated with indicated HCV RNA genomes and after 72 h, treated with 10 μM MDM2 inhibitor (nutlin-3) or DMSO for an additional 6 h. The numbers indicate the percentages of p53-positive cells following nutlin-3 treatment. (B) p53 accumulation in HCV core (-) versus HCV core (+) populations treated with 250 nM proteasome inhibitor (epoxomycin [EPX]) or DMSO for 6 h. The numbers indicate the percentages of p53-positive cells following EPX treatment.](https://figures.cochat.ai/paper-figures/52515bcb7ea14ead8d438fc98da5be70/hepatitis-c-virus-indirectly-disrupts-dna-damage-induced-p53-responses-by-figure-6.jpg)
![FIG 7 PKR is activated in HCV-infected cultured cells and during acute HCV infection in vivo. (A) Immunoblots of total PKR, active PKR (pT446), and HCV core protein in control and PKR knockout (PKRKO) HepG2/miR-122 cells 72 h after electroporation with the indicated HCV RNA. β-Actin was used as a loading control. (B) Flow cytometric analysis of activated PKR (pT446) in HCV core (-) and HCV core (+) populations of control HepG2/miR-122 cells. (C) Detection of phospho-PKR (T446) in chimpanzee liver by immunohistochemistry (IHC). Representative images of liver sections stained for phospho-PKR are shown for animal 4X0395 at 6 weeks prechallenge (wk -6) or at 6 or 11 weeks postchallenge with HCV. The far right panel shows a liver section from animal 4X0395 at week 11 that was stained according to the same protocol but with the omission of the primary antibody (Ab). Bars = 100 µm. (D) Diagram showing workflow of image analysis and phospho-PKR (p-PKR) quantitation in IHC images. Hepatocytes were identified based on size and nuclear hematoxylin stain. Hemosiderin deposits were evident in some samples, and these regions were excluded from analyses. The magenta chromogen (phospho-PKR) was quantified on a per cell basis and categorized as absent/low, medium, or high based on the observed range. (E) Quantitation of phospho-PKR in liver sections from three chimpanzees pre- and postchallenge with HCV. For each time point, viral loads in serum and liver (expressed as genome equivalents [GE]) and serum alanine aminotransferase (ALT) levels are shown.](https://figures.cochat.ai/paper-figures/4707b58180aa4daaaffcccb2e3a3dd3b/hepatitis-c-virus-indirectly-disrupts-dna-damage-induced-p53-responses-by-figure-7.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, p53 is mutated or altered in multiple immortalized cell lines 62,63 , resulting in altered DDR.”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · cited 1×
“edu), and oligonucleotides encoding this target sequence were annealed and inserted into BsmBI-digested lentiCRISPRv2 vector (a gift from Feng Zhang; Addgene plasmid 52961) (49).”
MethodThe HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“p53 abundance is mainly regulated by the activity of the E3 ubiquitin ligase MDM2, which ubiquitylates p53, thereby targeting it for proteasomal degradation (22).”
BackgroundParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.-G., Mizokami, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1268 · Cited by 2,754 · cited 1×
“3 (45) or from the corresponding replication-incompetent controls pJFH1/GND (46) or pH77S/AAG (47) using the T7 RiboMax Express large-scale RNA production system (Promega, Madison, WI).”
MethodGuide for the Care and Use of Laboratory Animals (8th edn)
Albus, U. (2012) · Laboratory Animals · doi:10.1258/la.2012.150312 · Cited by 1,693
Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,453 · cited 7×
“Mutations that disrupt the regulation or function of p53 are present in the majority of human cancers, including HCC (9, 10).”
BackgroundInfluentialUnravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387 · cited 1×
“The p53 protein is a canonical tumor suppressor that restricts tumorigenesis by initiating antiproliferative processes such as cell cycle arrest, senescence, and apoptosis, in large part through its role as a transcription factor (8).”
Background(2018) · doi:10.1001/jama · Cited by 932
Transmission of Hepatitis C by Intrahepatic Inoculation with Transcribed RNA
Kolykhalov, A. A., Agapov, E. V., Blight, K. J., Mihalik, K., Feinstone, S. M., & Rice, C. M. (1997) · Science · doi:10.1126/science.277.5325.570 · Cited by 735 · cited 1×
“cells with synthetic genomic RNA (16, 19), as in the experiments described above.”
MethodHussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 621 · cited 7×
“Mutations that disrupt the regulation or function of p53 are present in the majority of human cancers, including HCC (9, 10).”
BackgroundInfluentialTreatment of Hepatitis C: A Systematic Review
Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S. (2014) · JAMA · doi:10.1001/jama.2014.7085 · Cited by 426 · cited 1×
“Recently developed direct-acting antivirals (DAAs) are highly effective in clearing chronic HCV infection (2).”
BackgroundAbnormal structure and expression of p53 gene in human hepatocellular carcinoma.
Bressac, B., Galvin, K. M., Liang, T. J., Isselbacher, K. J., Wands, J. R., & Ozturk, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1973 · Cited by 416 · cited 4×
“Attempts to determine whether p53 function is altered in cells infected with HCV have been hindered historically by the fact that Huh7 cells, which are permissive for HCV replication and typically used for cell culture studies of HCV infection, express a mutated, transcriptionally inactive form of p53 (12, 13).”
BackgroundInfluentialWilliams, B. R. G. (2001) · Science's STKE · doi:10.1126/stke.2001.89.re2 · Cited by 406 · cited 1×
“The antiviral protein kinase R (PKR) is activated upon binding dsRNA intermediates generated during virus replication, resulting in phosphorylation of the translation initiation factor eIF2 and global inhibition of protein synthesis (24).”
BackgroundLi, K., Chen, Z., Kato, N., Gale, M., & Lemon, S. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414139200 · Cited by 367 · cited 1×
“Huh7 and HepG2 cells were maintained as described previously (44).”
BackgroundSelf-citationYi, M., Villanueva, R. A., Thomas, D. L., Wakita, T., & Lemon, S. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510727103 · Cited by 357 · cited 1×
“3 (45) or from the corresponding replication-incompetent controls pJFH1/GND (46) or pH77S/AAG (47) using the T7 RiboMax Express large-scale RNA production system (Promega, Madison, WI).”
MethodSelf-citationMajumder, M., Ghosh, A. K., Steele, R., Ray, R., & Ray, R. B. (2001) · Journal of Virology · doi:10.1128/jvi.75.3.1401-1407.2001 · Cited by 255
Gale, M., Kwieciszewski, B., Dossett, M., Nakao, H., & Katze, M. G. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6506-6516.1999 · Cited by 250 · cited 1×
“Some early studies suggest that the HCV NS5A protein blocks this protective PKR host response (25), but immunoblotting revealed increased phosphorylation of PKR within HCV-infected HepG2/miR-122 cultures (Fig.”
BackgroundHCV NS5A interacts with p53 and inhibits p53-mediated apoptosis
Lan, K.-H., Sheu, M.-L., Hwang, S.-J., Yen, S.-H., Chen, S.-Y., Wu, J.-C., Wang, Y.-J., Kato, N., Omata, M., Chang, F.-Y., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205589 · Cited by 245
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines
Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsh, J. A., Sun, T., & Harris, C. C. (1993) · Carcinogenesis · doi:10.1093/carcin/14.5.987 · Cited by 241 · cited 2×
“Attempts to determine whether p53 function is altered in cells infected with HCV have been hindered historically by the fact that Huh7 cells, which are permissive for HCV replication and typically used for cell culture studies of HCV infection, express a mutated, transcriptionally inactive form of p53 (12, 13).”
BackgroundHepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R Phosphorylation
Garaigorta, U., & Chisari, F. V. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.11.004 · Cited by 228 · cited 2×
“These results are consistent with HCV-induced activation of PKR, which has been shown previously to restrict translation of antiviral interferon-stimulated genes (ISGs) in HCVinfected cell cultures (26).”
BackgroundVirus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer
McGivern, D. R., & Lemon, S. M. (2011) · Oncogene · doi:10.1038/onc.2010.594 · Cited by 219 · cited 3×
“HCV may promote early events in carcinogenesis by impairing the capacity of infected cells to respond appropriately to DNA damage (3, 4).”
BackgroundSelf-citationWieland, S., Makowska, Z., Campana, B., Calabrese, D., Dill, M. T., Chung, J., Chisari, F. V., & Heim, M. H. (2014) · Hepatology · doi:10.1002/hep.26770 · Cited by 180 · cited 1×
“It is interesting to speculate that the respective contributions of these pathways to carcinogenesis may depend upon HCV replication levels, which vary widely among infected hepatocytes both within and between patients (41, 42).”
BackgroundVisualizing Hepatitis C Virus Infections in Human Liver by Two-Photon Microscopy
Liang, Y., Shilagard, T., Xiao, S., Snyder, N., Lau, D., Cicalese, L., Weiss, H., Vargas, G., & Lemon, S. M. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.050 · Cited by 171 · cited 1×
“It is interesting to speculate that the respective contributions of these pathways to carcinogenesis may depend upon HCV replication levels, which vary widely among infected hepatocytes both within and between patients (41, 42).”
BackgroundSelf-citationRegulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation
Yamane, D., McGivern, D. R., Wauthier, E., Yi, M., Madden, V. J., Welsch, C., Antes, I., Wen, Y., Chugh, P., McGee, C. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3610 · Cited by 167 · cited 2×
“Unless otherwise indicated, HCV infections were initiated via electroporation with genome-length HCV RNA transcribed in vitro from molecular clones pJFH1-QL (17) or pH77S.”
BackgroundMethodSelf-citationChang, P.-C., Cw, C., Chau, G.-Y., Li, F.-Y., Tsai, Y.-H., Wu, J.-C., & Lee, Y.-H. W. (2005) · Oncogene · doi:10.1038/sj.onc.1209239 · Cited by 164
Otsuka, M., Kato, N., Lan, K.-H., Yoshida, H., Kato, J., Goto, T., Shiratori, Y., & Omata, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000578200 · Cited by 164
Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity
Ray, R. B., Steele, R., Meyer, K., & Ray, R. (1998) · Gene · doi:10.1016/s0378-1119(98)00030-4 · Cited by 155
Moradpour, D., Kary, P., Rice, C. M., & Blum, H. E. (1998) · Hepatology · doi:10.1002/hep.510280125 · Cited by 150 · cited 2×
“UHCV-11 cells (21) were maintained in DMEM supplemented with 500 g/ml G418 (ThermoFisher) and 10% Tet System Approved FBS (Clontech Laboratories, Mountain View, CA) in the presence or absence of 1 g/ml tetracycline.”
MethodHepatitis C Virus Induces E6AP-Dependent Degradation of the Retinoblastoma Protein
Munakata, T., Liang, Y., Kim, S., McGivern, D. R., Huibregtse, J., Nomoto, A., & Lemon, S. M. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030139 · Cited by 148
Self-citationKao, C.-F., Chen, S.-Y., Chen, J., & Lee, Y. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207368 · Cited by 145
Masaki, T., Arend, K. C., Li, Y., Yamane, D., McGivern, D. R., Kato, T., Wakita, T., Moorman, N. J., & Lemon, S. M. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.12.014 · Cited by 145 · cited 1×
“which is required for genome replication (15, 16).”
BackgroundSelf-citationShimakami, T., Welsch, C., Yamane, D., McGivern, D. R., Yi, M., Zeuzem, S., & Lemon, S. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.056 · Cited by 133 · cited 1×
“3 (45) or from the corresponding replication-incompetent controls pJFH1/GND (46) or pH77S/AAG (47) using the T7 RiboMax Express large-scale RNA production system (Promega, Madison, WI).”
MethodSelf-citationHepG2 Cells Expressing MicroRNA miR-122 Support the Entire Hepatitis C Virus Life Cycle
Narbus, C. M., Israelow, B., Sourisseau, M., Michta, M. L., Hopcraft, S. E., Zeiner, G. M., & Evans, M. J. (2011) · Journal of Virology · doi:10.1128/jvi.05843-11 · Cited by 133 · cited 8×
“cells with synthetic genomic RNA (16, 19), as in the experiments described above.”
BackgroundMethodInfluentialSelf-citationGlobal control of hepatitis C virus
Cox, A. L. (2015) · Science · doi:10.1126/science.aad1302 · Cited by 109 · cited 2×
“Hepatitis C virus (HCV) persistently infects ~3% of the global population, placing millions of infected individuals at risk for liver cirrhosis and hepatocellular carcinoma (HCC), the most common form of primary liver cancer (1).”
BackgroundDeng, L., Nagano‐Fujii, M., Tanaka, M., Nomura-Takigawa, Y., Ikeda, M., Kato, N., Sada, K., & Hotta, H. (2006) · Journal of General Virology · doi:10.1099/vir.0.81735-0 · Cited by 102
Sheahan, T. P., Imanaka, N., Marukian, S., Dorner, M., Liu, P., Ploß, A., & Rice, C. M. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.01.007 · Cited by 98 · cited 1×
“Furthermore, virus replication levels are low, and detection of infected cells requires sensitive reporter genes (14).”
Backgroundp53-dependent transcriptional repression of p21waf1 by hepatitis C virus NS3
Kwun, H. J., Jung, E. Y., Ahn, J. Y., Lee, M. N., & Jang, K. L. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-9-2235 · Cited by 98
Genome guardian p53 and viral infections
Sato, Y., & Tsurumi, T. (2012) · Reviews in Medical Virology · doi:10.1002/rmv.1738 · Cited by 96 · cited 2×
“p53 is also frequently targeted by oncogenic DNA viruses, which encode proteins that inactivate p53 as a means to escape cell cycle arrest and apoptosis (11).”
BackgroundComplex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor
Ishido, S., & Hotta, H. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01312-x · Cited by 96
Hepatitis C Virus Infection Causes Cell Cycle Arrest at the Level of Initiation of Mitosis
Kannan, R. P., Hensley, L., Evers, L. E., Lemon, S. M., & McGivern, D. R. (2011) · Journal of Virology · doi:10.1128/jvi.00280-11 · Cited by 93
Self-citation‘Liver let die’: oxidative DNA damage and hepatotropic viruses
Higgs, M. R., Chouteau, P., & Lerat, H. (2014) · Journal of General Virology · doi:10.1099/vir.0.059485-0 · Cited by 89 · cited 1×
“On one hand, p53 suppression would be expected to impair cell cycle arrest and DNA repair within an infected liver that is rich in oxidative stress and prone to DNA damage (40).”
BackgroundDNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.
Caldecott, K. W., Banks, G. R., & Jeggo, P. A. (1990) · PubMed · Cited by 81
Qadri, I., Iwahashi, M., & Simon, F. R. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00315-4 · Cited by 80
Israelow, B., Narbus, C. M., Sourisseau, M., & Evans, M. J. (2014) · Hepatology · doi:10.1002/hep.27227 · Cited by 79 · cited 1×
“Although infection is inefficient in these cells (16, 20), we observed clear suppression of p53 accumulation and the absence of p21 upregulation specifically within HCV-infected cells following exposure to etoposide (Fig.”
BackgroundSelf-citationPotential contribution of tumor suppressor p53 in the host defense against hepatitis C virus†
Dharel, N., Kato, N., Muroyama, R., Taniguchi, H., Otsuka, M., Wang, Y., Jazag, A., Shao, R., Chang, J., Adler, M. K., et al. (2008) · Hepatology · doi:10.1002/hep.22176 · Cited by 65 · cited 1×
“Although some recent studies have claimed that the p53Y220C mutant present in Huh7 cell lines retains transcriptional activity (27, 28), our results show that this mutant is deficient in upregulating canonical p53 targets (Fig.”
ResultMilward, A., Mankouri, J., & Harris, M. (2009) · Journal of General Virology · doi:10.1099/vir.0.015305-0 · Cited by 64
Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response
Marques, J. T., Rebouillat, D., Ramana, C. V., Murakami, J., Hill, J. E., Gudkov, A., Silverman, R. H., Stark, G. R., & Williams, B. R. G. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11105-11114.2005 · Cited by 59 · cited 2×
“previously been described in the context of acute, nononcogenic RNA virus infections (39).”
BackgroundHarouaka, D., Engle, R. E., Wollenberg, K. R., Diaz, G., Tice, A. B., Zamboni, F., Govindarajan, S., Alter, H. J., Kleiner, D. E., & Farci, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516879113 · Cited by 54 · cited 1×
“However, the impact of HCV infection on these tumor suppressor pathways is unlikely to have any role in maintaining cellular transformation, as HCV replication is typically substantially reduced within HCC tissue in comparison to the surrounding cirrhotic liver (43).”
BackgroundHepatitis C Virus NS2 Protein Inhibits DNA Damage Pathway by Sequestering p53 to the Cytoplasm
Bittar, C., Shrivastava, S., Chowdhury, J. B., Rahal, P., & Ray, R. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062581 · Cited by 48
Dixit, U., Pandey, A. K., Liu, Z., Kumar, S., Neiditch, M. B., Klein, K. M., & Pandey, V. N. (2015) · Journal of Virology · doi:10.1128/jvi.00729-15 · Cited by 37 · cited 1×
“Although some recent studies have claimed that the p53Y220C mutant present in Huh7 cell lines retains transcriptional activity (27, 28), our results show that this mutant is deficient in upregulating canonical p53 targets (Fig.”
ResultPromotion of Hepatocellular Carcinoma by Hepatitis C Virus
Bühler, S., & Bartenschlager, R. F. W. (2012) · Digestive Diseases · doi:10.1159/000341688 · Cited by 21 · cited 3×
“HCV may promote early events in carcinogenesis by impairing the capacity of infected cells to respond appropriately to DNA damage (3, 4).”
Background
Research works printed but not linked: 2
- National Institutes of Health . 2002. Public Health Service policy on humane care and use of laboratory animals. Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD.
- US Department of Agriculture . 2013. Animal Welfare Act and animal welfare regulations. Animal and Plant Health Inspection Service, US Department of Agriculture, Washington, DC.
Cited by
Dash, S., Aydın, Y., Widmer, K., & Nayak, L. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s221187 · Cited by 141
Hedgehog Signaling: Implications in Cancers and Viral Infections
Iriana, S., Asha, K., Repak, M., & Sharma-Walia, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031042 · Cited by 75
Lunová, M., Smolková, B., Uzhytchak, M., Janoušková, K. Ž., Jirsa, M., Egorova, D., Kulikov, A. V., Kubinová, Š., Dejneka, A., & Lunov, O. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03321-z · Cited by 47
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32
“In addition, p53 is mutated or altered in multiple immortalized cell lines 62,63 , resulting in altered DDR. Vector-induced activation of DDR foci, in fl ammatory markers and gliosis were con fi rmed in vivo in mice in the context of IPa injection.”
AAV vectors trigger DNA damage responses and STING-dependent inflammation in human CNS cells
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Alezz, M. A., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2024) · doi:10.21203/rs.3.rs-4171795/v1 · Cited by 32
Metadata
- Authors
- Mitchell, J. K., Midkiff, B. R., Israelow, B., Evans, M. J., Lanford, R. E., Walker, C. M., Lemon, S. M., & McGivern, D. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Icahn School of Medicine at Mount Sinai (US)
- Texas Biomedical Research Institute (US)
- Nationwide Children's Hospital (US)
- Corresponding author
- Lemon, Stanley M.
- McGivern, David R.
- ORCID
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2017-05-03
- Volume
- 8
- Issue
- 2
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- PMC
- PMC5405228
- OpenAlex
- W2609960515
- Cited by
- 38
- References
- 52
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 2
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- mBio (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UNC Libraries
- Funders
- HHS | NIH | National Cancer Institute (T32-CA009156, F32-CA192633, R01-CA164029, P30-CA016086)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (T32-AI07647, R01-AI095690, R37-AI047367, R21-AI115207)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F30-DK096892, R01-DK095125)
- HHS | NIH | NIH Office of the Director (P51-OD011133)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatitis C virus, p53, PKR, DNA damage response, HCV replication, hepatocellular carcinoma, miR-122, etoposide, Nutlin-3, CRISPR/Cas9, double-stranded RNA, host-virus interaction, viral oncogenesis, chimpanzees
- MeSH terms
- Animals, Pan troglodytes, Disease Models, Animal, Hepatitis C, Humans, Tumor Suppressor Protein p53, Hepacivirus, eIF-2 Kinase, Host-Pathogen Interactions, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.